Correspondence 0001213900-24-108460 from Jabez Biosciences, Inc. (CIK 0002038185)
Jabez Biosciences, Inc. (CIK 0002038185)
Date: Dec. 12, 2024 · CIK: 0002038185 · Accession: 0001213900-24-108460
AI Filing Summary & Sentiment
File numbers found in text: 024-12509
Letter
United States Securities and Exchange Commission Office of Life Sciences Re: Jabez Biosciences, Inc. Amendment No. 3 to Offering Statement on Form 1-A Filed December 3, 2024 File No. 024-12509
Dear Mr. Gorsky and Mses. Gama, Torney and Mast,
We are in receipt of your comment letter dated in the above referenced matter and hereby respond to same as follows:
Amendment No. 3 to Offering Statement on Form 1-A
Regulatory Process, page 23
1. We note your response to prior comment 1 and reissue. You state that performance of clinical trials in accordance with good clinical practice is required. Please expand your disclosure to provide further details regarding the regulatory structure of the clinical trials referenced. As an example only, if your product candidate JBZ-001 must undergo Phase 1, 2, and 3 of clinical trials please provide a description of what each phase entails.
RESPONSE: We have amended the Form 1-A/A accordingly.
Respectfully Submitted,
/s/ Tamara
Jovonovich
Show Raw Text
CORRESP
1
filename1.htm
JABEZ BIOSCIENCES,
INC.
6393
Blackstone Dr.
Zionsville,
IN 46077
December 12, 2024
Doris
Stacey Gama
Joshua
Gorsky
Christine
Torney
Mary
Mast
United
States Securities and Exchange Commission
Office
of Life Sciences
Washington,
DC
Re:
Jabez
Biosciences, Inc.
Amendment No. 3 to Offering Statement on Form 1-A
Filed December 3, 2024
File No.
024-12509
Dear
Mr. Gorsky and Mses. Gama, Torney and Mast,
We
are in receipt of your comment letter dated in the above referenced matter and hereby respond to same as follows:
Amendment
No. 3 to Offering Statement on Form 1-A
Regulatory
Process, page 23
1. We
note your response to prior comment 1 and reissue. You state that performance of clinical trials in accordance with good clinical practice
is required. Please expand your disclosure to provide further details regarding the regulatory structure of the clinical trials referenced.
As an example only, if your product candidate JBZ-001 must undergo Phase 1, 2, and 3 of clinical trials please provide a description
of what each phase entails.
RESPONSE: We have amended the Form 1-A/A accordingly.
Respectfully Submitted,
/s/ Tamara
Jovonovich
Tamara Jovonovich, President